Blue Trust’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.9K Sell
396
-86
-18% -$2.98K ﹤0.01% 1633
2026
Q2
$18.8K Hold
482
– – ﹤0.01% 1677
2026
Q1
$15.7K Sell
482
-330
-41% -$10.6K ﹤0.01% 1714
2025
Q4
$28.6K Sell
812
-511
-39% -$18.1K ﹤0.01% 1559
2025
Q3
$34.8K Sell
1,323
-1,153
-47% -$34.4K ﹤0.01% 1524
2025
Q2
$65.6K Buy
2,476
+529
+27% +$13.9K ﹤0.01% 1245
2025
Q1
$47K Buy
1,947
+62
+3% +$1.96K ﹤0.01% 1395
2024
Q4
$75.9K Buy
1,885
+1,478
+363% +$84.3K ﹤0.01% 1052
2024
Q3
$21.6K Buy
+407
New +$23.9K ﹤0.01% 1914
2023
Q2
– Sell
-121
Closed -$1K – 2553
2023
Q1
$1K Hold
121
– – ﹤0.01% 2223
2022
Q4
$0 Sell
121
-67
-36% -$299 ﹤0.01% 2496
2022
Q3
$1K Buy
+188
New +$616 ﹤0.01% 2021

Other funds holding VKTX

Blue Trust's VKTX Position: Q3 2026 in Review

Blue Trust reduced its Viking Therapeutics (VKTX) stake by 18% in Q3 2026, selling an estimated $2.98K and leaving 396 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1633.

Blue Trust first reported a position in VKTX in Q3 2022 and has held it in 12 quarters since. The position peaked at $75.9K in Q4 2024. 359 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Blue Trust held 396 shares of Viking Therapeutics worth $12.9K as of Q3 2026.
  • Blue Trust sold 86 Viking Therapeutics shares in Q3 2026, an estimated $2.98K.
  • Viking Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #1633 holding.
  • Blue Trust first reported a position in Viking Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Blue Trust's Viking Therapeutics position peaked at $75.9K in Q4 2024.
  • 359 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.